Related Experiment Videos
Estrogen receptor signalling: bases for drug actions
Maria Marino1, Filippo Acconcia, Paolo Ascenzi
1Department of Biology, University Roma Tre, Viale G. Marconi, 446, I-00146 Roma, Italy. m.marino@uniroma3.it
Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|September 24, 2005
Summary
Estrogen receptors (ERalpha and ERbeta) mediate 17beta-estradiol (E2) effects through direct DNA binding, indirect transcription factor interactions, and rapid membrane signaling. Understanding these estrogen receptor mechanisms informs anti-cancer drug development.
Area of Science:
- Molecular Endocrinology
- Cellular Biology
- Pharmacology
Background:
- Estrogen receptors (ERalpha and ERbeta) are crucial for 17beta-estradiol (E2) functions in growth, development, and homeostasis.
- ERalpha and ERbeta act as ligand-dependent transcription factors, regulating gene expression via direct DNA binding to estrogen-responsive elements (EREs) or indirect mechanisms involving other transcription factors.
- Emerging evidence suggests a third signaling pathway involving cytoplasmic proteins and rapid membrane-initiated responses mediates mitogenic E2 effects, though ERbeta's role is debated.
Purpose of the Study:
- To review and summarize the latest findings on the multiple molecular mechanisms of 17beta-estradiol (E2) action.
- To highlight the evolving understanding of how E2 signaling pathways function.
- To discuss the development of anti-cancer drugs that modulate estrogen receptor signaling.
Main Methods:
- Literature review of recent scientific findings.
- Synthesis of information on ERalpha and ERbeta molecular mechanisms.
- Analysis of E2 signaling pathways and their role in cancer drug development.
Main Results:
- Estrogen receptors (ERalpha and ERbeta) mediate E2 effects through three distinct pathways: direct DNA binding, indirect transcription factor modulation, and rapid membrane-initiated signaling.
- The precise role of ERbeta in rapid, membrane-initiated E2 signaling remains an area of active investigation.
- Understanding these diverse E2 mechanisms is critical for developing targeted anti-cancer therapies.
Conclusions:
- Estrogen receptor signaling is complex, involving multiple molecular mechanisms that contribute to E2's diverse physiological roles.
- Further research into the rapid, membrane-initiated E2 pathway and ERbeta's involvement is warranted.
- Advances in understanding E2 signaling pathways are directly contributing to the development of novel anti-cancer drugs targeting estrogen receptor modulation.